acceler over-the-counter trump proair
friday may trump administr releas long-await plan
reign drug cost inflat includ direct fda acceler
approv non-prescript over-the-counter drug also announc
close expect receiv complet respons letter
file gener proair prevent launch proair reduc
ep lower estim see exhibit price
target howev view
administr focu over-the-counter far import
trump plan major posit potenti catalyst execut
branch intend direct fda acceler approv non-
prescript over-the-counter drug share over-the-counter store
brand would benefit fda previous note intent expand
over-the-counter access decemb consum healthcar america chca
repres approxim total sale segment profit
pre-corp expens refer februari initi report detail
trump plan monograph bill give us confid chca acceler
think chca sale growth may acceler
assumpt reli addit rx
over-the-counter switch owe part execut branch action
increment innov driven monograph reform bill recent
clear committe june quantifi rx sale may
switch over-the-counter
proair disappoint releas news soon
abl within hour receiv verbal confirm fda
thursday afternoon receiv fourth proair
still await detail regard believ
work bring import medic market continu fda
appear overli cautiou gener proair though
understand given rescu inhal counter agenc new
direct reduc drug cost view push
gener proair launch
overal continu view best-in-class store brand over-the-counter
categori expand year ahead driven govern
action rx over-the-counter switch studi conduct brand rx player
valu use discount cash flow model base fcff
discount rate termin ev/ebitda multipl
chang made note
buy chang
page analyst certif
perform rel
co plc engag product
over-the-count consum good
profit loss summari
growth margin
domin share privat label store brand
market solid presenc european brand over-the-counter
chca busi benefit renew regulatori
legisl focu over-the-counter
account oversight improv
chci busi stabil look pois growth
rx busi proven resili
challeng extern oper margin stabil high
low rang
recent hire new ceo uwe rhrhoff track
record effici oper typic deliv
promis think knowledg eu market help
continu success turnaround chci busi
valu use discount cash flow model base
fcff discount rate termin ev/ebitda
multipl
chang net debt
average cost debt
risk invest thesi
monograph reform bill pass could neg
impact assumpt increas innov penetr
over-the-counter medicin true fda act find
way eas rx-to-otc pathway risk thesi
includ increas competit gener pressur rx
busi expect turnaround eu stall
regulatori risk price risk litig risk busi
exhibit lower ep estim owe proair
exhibit june quantifi rx sale may potenti switch over-the-counter
inhal
valuat risk
price target vs prior base discount cash flow termin multipl
method discount rate termin ev/ebitda multipl
reduct price target due entir push back potenti launch gener
main risk thesi relat view regul legisl
regulatori legisl solut implement reduc
prescript drug cost inflat includ increas access non-prescript drug
posit impact think assumpt model
call acceler fundament may optimist risk thesi
includ increas competit gener pressur perrigo rx busi
expect turnaround eu stall regulatori risk price risk litig
risk busi develop risk among other
profit loss account
million unless otherwis note
sale
sale
sale
sale
sale
sale
sale
total expens
total expens
total expens
total expens
sale
sale
 year
reconcili gaap
reconcili gaap
reconcili gaap
reconcili gaap
million unless otherwis note
cash equival
prepaid expens
properti plant equip net
goodwil
payrol relat tax
accumul incom loss
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
million unless otherwis note
depreci amort
loss acquisition-rel fx
chang financi asset
tysabri chang fair valu
incom tax benefit stock option
excess tax benefit stock transact
loss sale invest
loss sale busi
loss extinguish debt
loss equiti method invest
amort debt discount premium
chang work capit
chang work capit
chang work capit
chang work capit
payrol relat tax
total chang work capit
oper activ
oper activ
oper activ
oper activ
acquisit busi
proce royalti right
settlement acquisition-rel fx
acquisit intang asset
addit properti equip
proce sale secur
proce sale pp
proce sale tysabri
proce sale busi
invest activ
invest activ
invest activ
invest activ
purchas non-controlling interest
repay long-term debt
borrow repay revolv
proce debt issuanc
premium earli retir debt
share withheld tax liabil
excess tax benefit stock transact
issuanc common stock
equiti issuanc
repurchas common stock
settlement conting consider
financ activ
financ activ
financ activ
financ activ
effect exchang rate cash
net chang cash
begin cash equival
end cash equival
end cash equival
end cash equival
end cash equival
capital-expenditure sale
